

**REMARKS/ARGUMENTS**

**35 U.S.C. § 112, second paragraph**

Claim 4 is rejected under 35 U.S.C. § 112, second paragraph, for allegedly failing to distinctly claim the subject matter of the invention. In making this rejection, the Examiner notes the terms “(C1-C6)acid”, “(C1-C6)ester”, “(C1-C6)ester-(C1-C6)alkyl-O-”, and “(C1-C6)alkoxy(C1-C6)ester.” Applicants hereby amend claim 4 by deleting the terms “(C1-C6)acid”, “(C1-C6)ester”, “(C1-C6)ester-(C1-C6)alkyl-O-”, and “(C1-C6)alkoxy(C1-C6)ester.”

Claims 1-4 and 14 are rejected under 35 U.S.C. § 112, second paragraph for allegedly failing to distinctly claim the invention. The Examiner notes that “s” is defined as one to five, but the pyridinyl ring which contains the (R<sup>3</sup>)<sub>2</sub> substituent or substituents does not allow for 5 substituents.


Claim 1 has been amended to define “s” as an integer from one to four. This amendment is supported by the specification on page 4, lines 28-29, where it states that s is preferably an integer from one to four. Reconsideration of and withdrawal of this rejection is respectfully solicited in view of the amendment to claim 1.

The Examiner has also objected to the term “heterocyclic” and suggested that it be changed to “heterocycle.” Claims 1 and 4 have been amended to change the term “heterocyclic” to “heterocycle.” Reconsideration of and withdrawal of this objection is respectfully solicited.

Prompt and favorable consideration of this application is respectfully requested. If the Examiner believes that personal communications will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Attorney Docket No. PC25698A  
Application No. 10/783,251  
Reply to Office Action of December 7, 2007

Respectfully submitted,



John H. Engelmann, Attorney  
Registration No. 28,075

Date: FEB. 28, 2008

Pfizer Inc.  
7000 Portage Road  
Kalamazoo, Michigan 49001  
Telephone No. (269) 833-2532  
Telefax No. (269) 833-8897